CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics公司已获得FDA批准，可启动CER-1236用于急性髓细胞白血病的I期临床试验的调查新药申请。
CERo Therapeutics, Inc. Receives FDA Clearance Of Its Investigational New Drug Application To Initiate A Phase 1 Clinical Trial Of CER-1236 For Acute Myelogenous Leukemia
CERo Therapeutics公司已获得FDA批准，可启动CER-1236用于急性髓细胞白血病的I期临床试验的调查新药申请。
资讯热榜
更新时间